Skip to main content
Unchecking box will stop auto data updates
Cboe BZX Real-Time Last Sale USD
Today's Change
Volume
Price Quote as of

Today's Trading

Day Low 65.83
Day High 67.24
Open:66.66
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Trailing Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

More stories below advertisement

Description
Emergent BioSolutions Inc. is strongly committed to the highest standards of ethical conduct and corporate governance. These standards are consistent with their corporate culture. The company understands that adhering to sound principles of corporate governance is critical to earning and maintaining the trust of their customers, employees and shareholders. The foundation of the corporate governance principles and practices are built on their reputation for openness, integrity and accountability. These are the principles that guide Emergent BioSolutions everyday. They have in place policies and practices to ensure that their Company is managed with integrity and in their shareholders' best interests. In addition, they are committed to meeting the requirements of federal and state law and the rules of the New York Stock Exchange.

Fundamentals

Market Capitalization, $M
Shares Outstanding, M
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio
Price/Book

Earnings

Corporate earnings are provided from Zacks Investment Research, including Income Statements, Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research – including Buy/Hold Recommendations, Earnings Surprises, Estimates and Recommendations History.

Stock Reports +

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

StockCalc Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

Latest Press Releases

Factors of Influence in 2018, Key Indicators and Opportunity within Emergent Biosolutions, LGI Homes, Surgery Partners, Overseas Shipholding Group, National Commerce, and comScore -- New Research Emphasizes Economic Growth
GlobeNewswire - Wed Sep 5, 6:45AM CDT
GlobeNewswire - CMTX
Wed Sep 5, 6:45AM CDT
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Emergent Biosolutions Inc. (NYSE:EBS), LGI Homes, Inc. (NASDAQ:LGIH), Surgery Partners, Inc. (NASDAQ:SGRY), Overseas Shipholding Group, Inc. (NYSE:OSG), National Commerce Corporation (NASDAQ:NCOM), and comScore, Inc. (NASDAQ:SCOR), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.
Emergent BioSolutions to Participate in Series of Near-Term Investor Conferences
GlobeNewswire - Fri Aug 17, 6:00AM CDT
GlobeNewswire - CMTX
Fri Aug 17, 6:00AM CDT
Emergent BioSolutions Inc. (NYSE: EBS) announced today that a member of the company's senior management team will participate in the following investor conferences during the third quarter and early portion of the fourth quarter of 2018:
CEPI Awards Contract Worth up to $36 million to Profectus BioSciences and Emergent BioSolutions to Develop Lassa Virus Vaccine
Globe Newswire - Thu Aug 16, 5:15AM CDT
Globe Newswire - CMTX
Thu Aug 16, 5:15AM CDT
OSLO, Norway, BALTIMORE and GAITHERSBURG, Md., Aug. 16, 2018 (GLOBE NEWSWIRE) -- CEPI (the Coalition for Epidemic Preparedness Innovations) today announced a new collaboration with Profectus BioSciences, Inc. and Emergent BioSolutions Inc. (NYSE: EBS) under which they will receive up to USD$36 million to advance the development and manufacture of a vaccine against the Lassa virus--an estimated 100,000 to 300,000 cases of Lassa virus infection occur each year.1
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 57.48 +14.82% increase
on 09/07/18
Period Open:59.43
Price movement based on the high, low and last over the given period.
67.24 -1.84% decrease
on 09/20/18
+6.57 (+11.06%) increase
since 08/20/18
3-Month 49.81 +32.50% increase
on 06/28/18
Period Open:53.63
Price movement based on the high, low and last over the given period.
67.24 -1.84% decrease
on 09/20/18
+12.37 (+23.07%) increase
since 06/20/18
52-Week 36.38 +81.42% increase
on 11/15/17
Period Open:37.62
Price movement based on the high, low and last over the given period.
67.24 -1.84% decrease
on 09/20/18
+28.38 (+75.44%) increase
since 09/20/17

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2018.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

More stories below advertisement